The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensiti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicine (Baltimore)
Hlavní autoři: Ma, Hu, Tian, Xu, Zeng, Xian-Tao, Zhang, Yu, Wang, Yi, Wang, Fei, Zhou, Jian-Guo
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2016
Témata:
5700
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718287/
https://ncbi.nlm.nih.gov/pubmed/26765461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002495
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky